Precision medicine for patients with gastro-oesophageal cancer: A subset analysis of the ProfiLER program

Background: Chemotherapy, anti-HER2 and PD-1 antibodies are standard treatments but only a minority of patients derive long-term benefit from these agents. Methods: In this report we describe the mutational landscape and outcome of patients with gastroesophageal cancers enroled in the ProfiLER progr...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Philippe A. Cassier, Clémentine Peyramaure, Valery Attignon, Lauriane Eberst, Camille Pacaud, Sandrine Boyault, Françoise Desseigne, Mathieu Sarabi, Pierre Guibert, Pauline Rochefort, Nathalie Marques, Michel Rivoire, Aurélien Dupré, Patrice Peyrat, Catherine Terret, Isabelle Ray-Coquard, Clélia Coutzac, David Pérol, Jean-Yves Blay, Olivier Trédan, Christelle de la Fouchardière
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2022
Materias:	Oesophageal cancer Gastric cancer Molecular alterations, molecular-targeted agents NGS CGH Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/af51f8a698dc4ce7a25e81ac463e3700
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Sea el primero en dejar un comentario!

Precision medicine for patients with gastro-oesophageal cancer: A subset analysis of the ProfiLER program

Ejemplares similares